Back to results
US 2003/0073682 A1Published application
Novel substituted aryl hydroxamic acids as metalloproteinase inhibitors
OwnerMatthew E. Voss, Carl P. Decicco +1inventors
InventorsMatthew E. Voss, Carl P. Decicco, Ruth R. Wexler
Life of this patent
Estimating the term…
Abstract
The present application describes novel substituted aryl hydroxamic acids of formula I: 1 or pharmaceutically acceptable salt forms thereof, wherein ring A is a 5-8 membered ring containing from 0-1 additional heteroatoms selected N, O, and S, which are useful as metalloprotease inhibitors.
Claims17
A compound of formula I:
- 81
- or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein;
- ring A is a 5-8 membered heterocyclic ring containing 0-1 additional heteroatoms selected from the group:
- O, NH, S, SO, and SO2, and substituted with 0-3 Ra;
- Ra, at each occurrence, is independently selected from the group:
- ═O, CH3, CH2CH3, CF3, Cl, F, OH, OCH3, and OCF3;
- Rb, at each occurrence, is independently F or CH3;
- X is selected from the group:
- CH2, C(O), C(O)O, C(O)NH, S(O), S(O)2, S(O)NH, and S(O)2NH;
- Y is selected from the group:
- (CH2)n, OCH2, CH2O, OCH(CH3), CH(CH3)O, OC(CH3)2, C(CH3)2O, OCF2, CF2O, S(O)pCH2, CH2S(O)p, NH, NHCH2, and CH2NH;
- Z is CH or N;
- R1 is selected from the group:
- H, F, Cl, Br, I, CH3, CH2CH3, CH(CH3)2, OCH3, OCH2CH3, OCH(CH3)2, CF3, and OCF3;
- R2 is selected from the group:
- F, Cl, Br, I, CH3, CH2CH3, CH(CH3)2, OCH3, OCH2CH3, OCH(CH3)2, CF3, and OCF3;
- R3 is selected from the group:
- F, Cl, Br, I, CH3, CH2CH3, CH(CH3)2, OCH3, OCH2CH3, OCH(CH3)2, CF3, and OCF3;
- provided that when Z is N, R2 and R3 are other than F, Br, or I;
- R4 is H;
- alternatively, R3 and R4 are taken together with the carbon atoms to which they are attached to form a 5-6 membered aromatic ring containing 0-2 heteroatoms selected from the group:
- O, S, NH, and N and substituted with 0-2 Rc;
- Rc is selected from the group:
- H, F, Cl, Br, I, NO2, CH3,
- CH2CH3, CH(CH3)2, OCH3, OCH2CH3, OCH(CH3)2, CF3, and OCF3;
- when R3 and R4 are taken together, then R2 is selected from the group:
- H, F, Cl, Br, I, CH3, CH2CH3, CH(CH3)2, OCH3, OCH2CH3, OCH(CH3)2, CF3, and OCF3;
- n is selected from the group:
- 1, 2, and 3;
- and,
- p is selected from the group:
- 0, 1, and 2.
29 more elements
A compound of formula II:
- 84
- or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein;
- ring A is a 5-8 membered heterocyclic ring containing 0-1 additional heteroatoms selected from the group:
- O, NH, S, SO, and SO2, and substituted with 0-3 Ra;
- Ra, at each occurrence, is independently selected from the group:
- ═O, CH3, CH2CH3, CF3, Cl, F, OH, OCH3, and OCF3;
- Rb, at each occurrence, is independently F or CH3;
- X is selected from the group:
- CH2, C(O), C(O)O, C(O)NH, S(O), S(O)2, S(O)NH, and S(O)2NH;
- Y′ is S or O;
- Z is CH or N;
- R1 is selected from the group:
- H, F, Cl, Br, I, CH3, CH2CH3, CH(CH3)2, OCH3, OCH2CH3, OCH(CH3)2, CF3, and OCF3;
- R2 is selected from the group:
- F, Cl, Br, I, CH3, CH2CH3, CH(CH3)2, OCH3, OCH2CH3, OCH(CH3)2, CF3, and OCF3;
- R3 is selected from the group:
- H, F, Cl, Br, I, CH3, CH2CH3, CH(CH3)2, OCH3, OCH2CH3, OCH(CH3)2, CF3, and OCF3;
- provided that when Z is N, R2 and R3 are other than F, Br, or
- R4 is H;
- alternatively, R3 and R4 are taken together with the carbon atoms to which they are attached to form a 5-6 membered aromatic ring containing 0-2 heteroatoms selected from the group:
- O, S, NH, and N and substituted with 0-1 Rc;
- Rc is selected from the group:
- H, F, Cl, Br, I, NO2, CH3, CH2CH3, CH(CH3)2, OCH3, OCH2CH3, OCH(CH3)2, CF3, and OCF3;
- when R3 and R4 are taken together, then R2 is selected from the group:
- H, F, Cl, Br, I, CH3, CH2CH3, CH(CH3)2, OCH3, OCH2CH3, OCH(CH3)2, CF3, and OCF3;
- n is selected from 1, 2, and 3;
- and,
- p is selected from 0, 1, and 2.
25 more elements
Dependencies are inferred from the claim text.